PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference

Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB), an innovative clinical-stage immunotherapy company, announced that its CEO, Dr. Frank Bedu-Addo, will present at the 33rd Annual Oppenheimer Healthcare Conference on March 14, 2023, at 8:00 AM ET. The event will be held virtually, and investors can register for the webcast here. PDS Biotech focuses on targeted immunotherapies for cancer and infections, leveraging proprietary platforms like Versamune® and Infectimune™. Their lead candidate, PDS0101, has shown promise in Phase 2 trials for HPV16-associated cancers.

FLORHAM PARK, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, will present at the 33rd Annual Oppenheimer Healthcare Conference being held virtually on March 13-15, 2023.

Oppenheimer Conference 
Presentation Date: Tuesday, March 14, 2023
Time: 8:00 AM ET
Investors can register for the webcast here

Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, PDS Biotechnology.

About PDS Biotechnology 
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune^®, PDS0301, and Infectimune™ T cell-activating platforms. We believe our targeted Versamune^® and PDS0301 based candidates have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead Versamune^® clinical candidate, PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital

Media Contacts: 
Tiberend Strategic Advisors, Inc.
Dave Schemelia 
Phone: +1 (609) 468-9325 
dschemelia@tiberend.com  

Bill Borden 
Phone: +1 (732) 910-1620 
bborden@tiberend.com

FAQ

What is the date and time of PDSB's presentation at the Oppenheimer Healthcare Conference?

PDS Biotechnology's presentation at the Oppenheimer Healthcare Conference is scheduled for March 14, 2023, at 8:00 AM ET.

Where can I register for the PDSB conference webcast?

Investors can register for the webcast of PDSB's conference presentation here.

What is the focus of PDSB's research and development?

PDS Biotechnology focuses on developing targeted immunotherapies for cancer and infectious diseases, utilizing platforms like Versamune® and Infectimune™.

What advancements have been made with PDSB's lead candidate, PDS0101?

PDS0101 has shown the ability to reduce tumors and stabilize disease in Phase 2 clinical trials for HPV16-associated cancers.